Sanofi Pasteur plans to discontinue production of Bacillus Calmette-Guérin (BCG) for the US market by mid-2017, startling physicians and patients who fear that a shortage of the widely used bladder cancer therapy will develop.
Robert L. Grubb III, MD, an associate professor of Surgery at Washington University School of Medicine in St. Louis, said in an interview, “It’s frustrating for urologists to try to explain to patients why this drug, which has been around for years, is not available to them.”
Past Supply Shortage
BCG is an intravesical immunotherapy that is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder and for the prevention of primary or recurrent stage Ta or T1 papillary tumors following transurethral resection.
... to read the full story